Abstract
Introduction

29
Today cancer ranges among the principal causes of morbidity and mortality worldwide and the World Health 30
Organization expects a 70 % increase in the number of new cases over the next two decades. 1 For many years 31
Cisplatin has been the choice of treatment for a wide range of cancers, e.g. ovarian, testicular, head and neck, 32 bladder and lung cancer. 2 However, the efficiency of Cisplatin is limited by acquired or intrinsic resistance 3 and 33 by severe side effects such as ototoxicity, peripheral neuropathy, myelosuppression and nephrotoxicity.
4 34 35 Consequently, focus is shifting towards the discovery of novel improved anti-cancer drugs and numerous new 36 compounds are synthesized in the search of a promising drug candidate. In the initial work of selecting a 37 candidate with an ideal profile, determination of IC 50 values, apoptotic studies and cell cycle checkpoint assays 38 are usually performed. However, knowledge on the stability of the compound and the mechanism of action is 39 also very valuable when deciding on the further fate of a new compound. Particularly, the latter is of significant 40 importance as a mechanism of action dissimilar to that of Cisplatin may be able to overcome Cisplatin 41 resistance, and hence improve anti-cancer therapy. 42 43 The purpose of the current work was to characterize the novel C,N-cyclometalated [(η 6 -p-cym)RuCl(κ
= deprotonated 1-bytyl-2-phenyl-benzimidazole carboxylate complex GY34 (Fig. 1 , published by Yellol et al. 5 ) 45 applying a more diverse approach than usually employed, addressing both biological and chemical aspects of 46 the compound. GY34 has been shown to exert an increased cytotoxic activity compared to Cisplatin in 47 colorectal adenocarcinoma HT29 cells (IC 50 GY34: 2.2 ± 0.4 µM, IC 50 Cisplatin: 9.5 ± 0.2 µM), in human breast 48 cancer T47D cells (IC 50 GY34: 5.5 ± 0.2 µM, IC 50 Cisplatin: 38 ± 2 µM) and in Cisplatin-resistant human ovarian 49 cancer A2780 cells (IC 50 GY34: 6.4 ± 0.1 µM, IC 50 Cisplatin: 15 ± 1 µM). 5 Moreover, GY34 arrests cells in the S 50 phase of the cell cycle and induces apoptosis of HT29 cells. 5 Finally, the level of metal accumulation in T47D 51 cells was increased after treatment with GY34 relative to treatment with Cisplatin. 5 Altogether this presents 52 GY34 as a potential future drug candidate for anti-cancer treatment and signifies the importance of further 53 investigation of the compound. 54 55
Experimental
57
Reagents 58
All reagents were analytical grade and purchased from Sigma-Aldrich (St. Louis, MO, USA) unless otherwise 59 stated. 60 61
The Ru-based compound GY34 was synthesized as described elsewhere 5 in the research group of Prof. José 62
Ruiz, Department of Inorganic Chemistry, University of Murcia, Spain. 1 mM stock solutions of GY34 were 63 prepared in DMSO. For cell experiments volumes of 1 mM GY34 stock solutions in DMSO were added directly 64 to the cell medium to obtain the preferred concentration. GY34 concentrations applied in the various 65 experiments were selected on the basis of the IC 50 value for human ovarian cancer A2780 cells reported by 66 Yellol et al. 5 (refer to Introduction). The applied concentration of Cisplatin was based on previously performed 67 caspase 3 activity assay. PBS for cell culturing and cell fractionation consisted of 137 mM NaCl, 2.6 mM KCl, 6.5 mM Na 2 HPO 4 and 1.5 73 mM KH 2 PO 4 , pH 7.4. KCl-Tris buffer used for cell fractionation consisted of 100 mM KCl, 50 mM Tris-HCl, 5 mM 74
MgCl 2 , 1 mM Na 2 EDTA, pH 7.4. Lysis buffer consisted of 1 % SDS, 150 mM NaCl, 20 mM HEPES, 1 mM EDTA, 0.5 75 % Triton X-100, 1 mM NaVO 3 and 1 % protease inhibitor. Percoll (GE Healthcare, Wauwatosa, WI, USA) 76 solutions were prepared in KCl-tris buffer. The isotonic NaCl medium and MgCl 2 solution used for taurine flux 77 experiments contained 143 mM NaCl, 5 mM KCl, 1 mM Na 2 HPO 4 , 1 mM Nebulizer gas flow was 0.9 mL/min while RF power and lens voltage were optimized on a daily basis. A 10 ppb 113
Ru standard prepared in 0.1 % HCl and 0.65 % HNO 3 yielded a signal of ~142000 counts. 1 µM solutions of GY34 114 (corresponding to 100 ppb Ru) in mobile phase and Roswell Park Memorial Institute (RPMI-1640) cell medium, 115 respectively, were analyzed immediately after preparation and after 24 h at room temperature. 116 117
In order to elucidate the structure of the various GY34 species indicated by the RP-HPLC-ICP-MS analysis RP-118 HPLC-ESI-MS was performed using the same HPLC system and parameters as described above, but with a 119 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Binding of GY34 to cytosolic biomolecules 216
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The distribution of GY34 between high-and low-molecular species in the cytosol was studied using centrifugal 217 filtration. ELA cells were grown to 80-90 % confluence in a 175 cm 2 culture flask at 37 °C, 5 % CO 2 , 100 % 218 humidity and were then incubated with 10 µM GY34 for 18 h at the same conditions. The cytosol was isolated 219 by the following procedure: After removing the cell medium the cells were washed twice in 10 mL PBS and the 220 PBS was removed. 250 µL lysis buffer was added, the cells were collected using a rubber policeman, sonicated 221 and centrifuged (5 min/20000 G/4 °C). The resulting supernatant (cytosol) was collected. An exact volume of 222 the cytosol was then fractionated using 3 kDa Amicon Ultra 2 mL spin filters (EMD Millipore, Billerica, MA, 223 USA). The cytosol was centrifuged (60 min/4500 G/4 °C) and the filtrate (<3 kDa fraction) was collected. The 224 filter was reversed, centrifuged (15 min/1500 G/4 °C) and the concentrate (>3 kDa fraction) was collected. The 225 content of GY34 in the <3 kDa and >3 kDa fractions and the unfractionated cytosol was determined as 226 described above. The experiment was performed in triplo, i.e. on three different passages of ELA cells. 227 228
Taurine flux assays 229
Taurine uptake via the taurine transporter (TauT) as well as taurine release under isotonic conditions from 230 A2780 WT, A2780 RES and ELA cells grown in the presence of either 5 µM Cisplatin or 5 µM GY34 for 18 h were 231 determined by tracer technique at room temperature as previously described. 8, 9 For influx experiments cells 232 were grown to 80 % confluence in 6-well polyethylene culture plates (9.6 cm 2 per well). Five wells were used to 233 determine the taurine uptake and the residual well was used to determine the representative protein content 234 in a well. Cells were washed three times with isotonic NaCl medium and left with 600 µl isotonic NaCl medium. 235
Influx was initiated by addition of 50 µL 3 H-taurine stock solution containing 37000 Bq/mL (0.005 µM taurine) 236 to well 1-5 at time 0, 2, 4, 6 and 8 min. Influx was terminated by removal of the extracellular medium at time 237 10 min, rapid rinse of cells by addition/aspiration of 1 mL ice-cold MgCl 2 solution, followed by cell lysis with 96 238 % ethanol. After evaporation of ethanol, 3 H-activity was extracted with ddH 2 O and determined in a Perkin 239 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 Elmer scintillation counter using Ultima Gold TM . The cellular taurine content (nmol⋅g protein Apoptosis studies on cells exposed to Cisplatin and GY34 were performed by flow cytometry. 10 5 ELA cells were 260 seeded in 2 mL RPMI-1640 cell medium in 6-well plates and incubated for 24 h at 37 °C, 5 % CO 2 . Cells were 261 subsequently exposed to 5 µM GY34 or 5 µM Cisplatin for 18 h under the same conditions. One well remained 262 untreated serving as a control. After incubation the cell medium was collected and the cells detached by 263 trypsination (0.25 % trypsin/0.5 mM EDTA in 1 mL PBS, 37 °C, 3 min). Trypsin was inactivated by addition of 1 264 mL cell medium. The resulting 2 mL cell suspension was added to the collected cell medium hence permitting 265 both floating and adherent cells to be considered in the assay. The cells were centrifuged (10 min/250 G) and 266 the precipitated cells washed twice in 1 mL PBS. PBS was removed after the final centrifugation and cells were 267 resuspended in 160 µL incubation buffer. 
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Results and discussion
274
In this work the novel Ru-based complex GY34 (Fig. 1) 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 Stability of GY34 in cell medium and mobile phase 279
The stability of GY34 in dilute solution was evaluated applying RP-HPLC-ICP-MS analysis. 1 µM solutions of 280 GY34 in mobile phase (20 mM ammonium acetate in 65 % v/v MeOH, pH 6.8) and RPMI-1640 cell medium, 281 respectively, were analyzed immediately after preparation and after 24 h at room temperature. The results are 282 outlined in Fig. 3 . The chromatograms obtained immediately after preparation of the GY34 solutions both 283 contain one large peak (t r ~4.5 min) that most likely can be assigned to GY34. After 24 h at room temperature a 284 second large peak (t r ~2 min) appears. This indicates that GY34 at room temperature is transformed to another 285
Ru-containing species and that the transformation occurs in both mobile phase and cell medium. 286 287
The structures of the GY34 species were attempted elucidated by RP-HPLC-ESI-MS. A 1 mM GY34 solution 288 prepared in DMSO and RPMI-1640 cell medium (20:80 % v/v) was analyzed immediately after preparation 289 (total ion chromatogram (TIC) displays one large peak at t r ~4.5 min and a smaller peak at t r ~2 min, not 290
shown) and after 24 h at room temperature ( species is not expected to occur in solution but rather as a result of an interaction between GY34 and DMSO in 302 the ESI-MS interface. The mass spectrum of the ~2 min TIC peak (not shown) did not allow for structure 303 elucidation of the related Ru species as the characteristic Ru isotopic pattern was absent. An explanation could 304 be that the ~2 min TIC peak corresponds to a GY34 subspecies that is fragmented during ESI leaving the Ru-305 containing fragment unionized and hence not detectable by ESI-MS, but still able to produce a signal in ICP-MS 306 as it contains Ru. 307 308 Figure 5 demonstrates that the chloride of GY34 is removed immediately after dissolving the compound in cell 309 medium or mobile phase. In addition to this GY34 is transformed to several different species as a function of 310 time. Thus the cytotoxic activity of GY34 proposed by Yellol et al. 5 is most likely not caused by GY34 itself but 311 instead by a subspecies of the compound. This is in accordance with the knowledge that Cisplatin as well in 312 solution is hydrolyzed, exchanging one or both chlorides with water. 10 The possible transformation in solution 313 of newly synthesized metallo-drugs should therefore be kept in mind when performing experiments. 314 315
Another important aspect of stability in solution is the solubility of the analyte. By NMR it has been shown that 316 GY34 is soluble in pure DMSO at 20 mM concentration, and that 200 µM GY34 solutions prepared in 10 % 317 DMSO are stable in up to 48 h. 11 Slightly soluble compounds often precipitate over time and the actual 318 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 concentration applied when performing experiments may not be consistent with the expected concentration. 319
Page 8 of 25 Metallomics
In the current work the intracellular distribution of GY34 was investigated as described below. For these 320 experiments GY34 was added to the cell medium to obtain a nominal concentration of 10 µM. After incubation 321
an aliquot of the cell medium was taken out and the GY34 concentration was determined by ICP-MS analysis. 322
Interestingly, actual GY34 concentrations in the cell medium were found to range between ~2-10 µM for 323 different replicates. As discussed below the intracellular distribution of GY34 appears to be dependent on the 324 GY34 concentration in the cell medium during incubation. Once more, this establishes analyte stability as a very 325 critical parameter and stresses the significance of evaluating and controlling the actual analyte concentration 326 throughout experiments. 327 328
The limited solubility of GY34 in the cell medium also signifies the importance of the procedure used to prepare 329 samples for ICP-MS analysis. Simply filtering and diluting the samples will cause potentially precipitated GY34 330 to be lost and lead to erroneous results. In this work the samples were digested at 60 °C using 65 % HNO 3 and 331 30 % H 2 O 2 , with nuclei even requiring microwave digestion. Thus, should some GY34 precipitate in the samples 332 prior to ICP-MS determination the result will not be affected as the sample preparation procedure will cause all 333 GY34 to be dissolved. 334 335
Intracellular distribution of GY34 336
In order to obtain knowledge on the mechanism of action of GY34 the intracellular distribution of the 337 compound in ELA cells was investigated. The cells were incubated for 18 h with nominally 10 µM GY34 and 338 afterwards the cell suspension was fractionated to a nuclear, a mitochondrial and a cytosolic fraction applying 339 a novel protocol developed for this work (refer to Fig. 2 and the experimental section Cell Fractionation). The 340 content of GY34 in each fraction was determined by ICP-MS analysis and the result appears from Table 1.  341 According to Table 1 most of the GY34 taken up by the ELA cells is located in the cytosol and the mitochondria. 342
This indicates that GY34 might target mitochondria in contrast to Cisplatin which is known to target DNA in the 343 cell nucleus. 12 ELA cells are known to be resistant to Cisplatin 6 and the ability of GY34 to induce apoptosis in 344 ELA cells (see below) might therefore arise from a different mechanism of action of GY34 compared to that of 345 Cisplatin. 346 347
As mentioned above, the concentration of GY34 in the cell medium during incubation varied between 348
replicates. Interestingly, the concentration in the cell medium appeared to affect the intracellular distribution 349 on GY34. For replicate 2-3 (~10 µM GY34 detected in cell medium) more GY34 was located in the mitochondria 350 compared to the nuclei (Table 1) , on the other hand for replicate 1 (~2 µM GY34 detected in cell medium) 32 351 %, 10 % and 58 % of GY34 taken up by the cells were located in nuclei, mitochondria and cytosol, respectively. 352
This indicates that GY34 at low concentrations is distributed primarily to the cell nuclei whereas the compound 353 in higher concentrations also targets the mitochondria. Possibly, GY34 targets the cell nuclei until saturation is 354 obtained, after which GY34 distribution to the mitochondria is initiated. It should be noted that the differing 355 intracellular GY34 distribution between replicates is not owing to the applied cell fractionation procedure but 356 rather related to the stability difficulties of GY34 in the cell medium. Applying the method on A2780 WT cells 357 incubated with 10 µM Cisplatin yielded 1 ± 0.3 % Cisplatin in the nuclei, 6 ± 0.9 % in the mitochondria and 93 ± 358 0.6 % in the cytosol (n = 3), demonstrating a satisfying reproducibility between replicates. 359 360
The importance of obtaining clean fractions when predicting the intracellular distribution of a compound is 361 stressed by the elevated content of GY34 in cytosol compared to nuclei and mitochondria. Should the nuclei or 362 mitochondria be contaminated with cytosol a misleadingly higher nuclear or mitochondrial content of GY34 363 would appear leading to false deductions on the mechanism of action. In this work SDS page and western 364 blotting were performed to evaluate the purity of the obtained fractions. The result appears from Fig. 6 . 365
Consulting Fig. 6 it can be seen that the nuclei as expected contain histone H3 (HIST, marker for nuclei) but do 366 not contain malate dehydrogenase 2 (MDH, marker for mitochondria) or lactate dehydrogenase B (LDH, marker 367 for cytosol). Thus, the nuclear fraction is not contaminated with either mitochondria or cytosol. In the same 368 manner the cytosol contain LDH but not HIST or MDH and the cytosol fraction is therefore not contaminated 369 with histone or mitochondria. The mitochondria contain a substantial amount of MDH and no HIST however a 370 very faded band for LDH is visible. This could indicate a minor contamination of the mitochondrial fraction with 371 cytosol. Conversely, the observed LDH in the mitochondria could also very likely originate from LDH embedded 372 in the inner mitochondrial membrane 13 and would thus not be due to contamination with cytosol. Repeated 373 wash of the mitochondria (refer to step (x) in Fig. 2 and the experimental section Cell Fractionation) ought to 374 have removed most of the cytosol from the surface of the mitochondria. Still, it cannot be ruled out that a 375 small amount of cytosol has diffused into the inner membrane space of the mitochondria causing a minor 376 contamination. Based on the above the authors believe that the purity of mitochondrial fractions obtained 377 using the current fractionation protocol is sufficient and that a minor content of cytosol in the inner 378 mitochondrial membrane is insignificant. 379 380
Several examples of subcellular fractionation and isolation of subcellular organelles are described in the 381 literature. 14-18 However, to the knowledge of the authors no procedures with features identical to the current 382 presented fractionation method have been reported. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 LDH located in the inner mitochondrial membrane 13 as discussed above remains unsettled. The nuclear and 398 cytosolic fractions are clean. 18 In order to map the intercellular distribution of a compound obtaining clean 399 fractions is of high importance. Also, the method must be able to fraction cells into nuclei, mitochondria and 400 cytosol. The authors believe that the fractionation method presented in this work features both. In addition the 401 method is less expensive than the commercially available fractionation kits. 402 403 A critical step in the fractionation procedure is the homogenization (step (ii), Fig. 2 ). Applying too much force 404 will break the mitochondria resulting in a reduced yield of mitochondria along with mitochondrial 405 contamination of the cytosol. Conversely, when too little a force is applied, only a minor part of the cells will be 406
homogenized. This results in a decreased mitochondrial yield as well and will furthermore contribute to the 407 contamination of the nuclei with unbroken cells.
Step (iii) in the fractionation procedure serves to precipitate 408 the nuclei which subsequently can be removed. However, should the homogenate contain small, unbroken 409 cells with a density similar to nuclei the nuclear fraction will be contaminated with unbroken cells and western 410 blot bands for LDH and MDH will appear. The probability of nuclear contamination with small, unbroken cells 411 increases with the number of unbroken cells that again depends on the force applied during homogenization. 412
To validate the quality of the homogenization SDS page gel electrophoresis and western blotting should always 413 be performed in connection with a fractionation. 414 415
In order to evaluate the amount of GY34 lost during the fractionation the mass balance was calculated. Prior to 416 homogenization a volume of unbroken cells was sampled allowing the total amount of GY34 taken up by the 417 cells to be determined by ICP-MS analysis. The mass balance was then obtained by relating the sum of the 418 GY34 detected in the nuclear, mitochondrial and cytosolic fractions to the total GY34 taken up by the cells. 31 ± 419 9 % (average ± SD, n = 3) of the total GY34 taken up by the cells was recovered in the fractions. A portion of 420 GY34 was probably lost with the unbroken cells and some degree of loss is to be expected from the numerous 421 wash and decant steps in the procedure. Finally, the effort to avoid contamination of the fractions also causes 422 a loss: e.g. when decanting a supernatant a part of the supernatant had to be left on top of the pellet to ensure 423 no pellet was transmitted. Thus, a trade-off between fraction purity and metal recovery must be made. 424
Although a relatively small amount of GY34 was recovered in the fractions the authors do not believe that it 425 effects the obtained distribution of GY34 in the cells. In the work of Zayed et al. mentioned above a platinum 426 recovery of >99 % was obtained after subcellular fractionation carried out using an extraction kit. 17 Apparently, 427 the attained fractions were not washed to the same extent as the current fractionation method requires, which 428 most likely explains the improved recovery. In this work fraction purity was prioritized due to its significance 429 when determining the intracellular distribution, as discussed earlier.
431
Binding of GY34 to cytosolic biomolecules 432
Another way to gain knowledge on the mechanism of action of a new compound is to study whether it binds to 433 biomolecules in the cell. As reviewed by de Almeida at al. 21 and Casini & Reedijk 22 there is every indication that 434 the biodistribution, uptake and pharmacological action of metallo-drugs depend on interactions with proteins. 435
In this work ELA cells were incubated with 10 µM GY34 for 18 h and the cytosol was isolated and fractionated 436 by 3 kDa spin filters. The GY34 content in the resulting two fractions was determined by ICP-MS analysis. 96 ± 437
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indicates that in the cytosol the majority of GY34 is bound to high-molecular biomolecules, most likely proteins, 439
and that only a minor part of the compound remains unbound or bound to small molecules. Thus the 440 cytotoxicity of GY34 is most likely facilitated by interaction with protein targets. 441 442 Similar experiments were carried out by Kasherman et al. with Cisplatin on A2780 cells suggesting that two-443 thirds of Cisplatin was associated with >3 kDa species. 23 This supports the hypothesis that metallo-drugs bind to 444 proteins once inside the cytosol instead of remaining unbound. The hypothesis is to some extent supported by 445 the work of Heffeter et al. Performing SEC-ICP-MS on cytosol of human cervical carcinoma-derived KB-3-1 cells 446 treated with the Ru-based drug KP1019 and its sodium salt KP1339 they found that after 3 h the majority of Ru 447 was found in the >150 kDa fraction and that Ru was redistributed to the <40 kDa fraction after 24 h. In order to validate that no GY34 was lost in the spin filters the GY34 content in the unfractionated cytosol was 450 determined as well, allowing calculation of the mass balance. 91 ± 9 % (average ± SD, n = 3) of the total 451 cytosolic GY34 was located in the <3 kDa and >3 kDa fractions validating an insignificant loss of GY34 during the 452 centrifugal filtration. 453 454
Effect of GY34 on organic osmolyte flux 455 Cells exposed to physiological or cytotoxic stimuli are eliminated by apoptosis which is a genetically well-456 orchestrated cellular process. Apoptosis is characterized by an initial cell shrinkage (apoptotic volume 457 decrease), which reflects net loss of ions, organic osmolytes and water. 25, 26 It has been shown that onset of 458 apoptosis can be postponed/prevented by limitation of the activity of volume-sensitive and volume-insensitive 459 leak pathways, that normally facilitate loss of the organic osmolyte taurine, and/or up-regulation of Na + -460 dependent transporters, e.g. TauT that facilitates taurine accumulation. 27 Taurine accounts for about 0.1 % of 461 our total body weight 28 and besides being an important organic osmolyte in mammalian cells taurine is 462 recognized for its role in foetal development, lung function, mitochondrial function, antioxidative defense and 463 as a modulator of the apoptotic response once it has been initiated. 27 Cisplatin resistance in ELA cells, when 464 compared to Cisplatin-sensitivity in EATCs, has previously been demonstrated to correlate with less nuclear 465
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